GRAL
VENTE TOTALE: 5 000 titres (~425 098,00 $ US)
- Insiders
- Ofman Joshua J.
- Total bought
- —
- Total sold
- $425,098
- Last activity
- 2026-08-27
- Last synced
-
2026-09-02 21:34:12
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-01
GRAL presents a deeply distressed financial profile with chronic cash burn, negative EBITDA, and no visible path to profitability, despite adequate near-term liquidity.
The first sentence of the analysis written for GRAL on 2026-09-01 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | -42.5% | -62.1% | -102.7% | -209.6% | -684.4% | |
| Ebit Margin | -363.2% | -611.7% | -855.9% | -1336.6% | -8659.0% | |
| Ebitda Margin | -257.0% | -485.8% | -685.5% | -1058.0% | -8259.0% | |
| Operating Profit Margin | -363.0% | -1743.0% | -1627.6% | -9798.2% | -8659.6% | |
| Pretax Profit Margin | -363.2% | -1721.7% | -1619.3% | -9795.5% | -8659.0% | |
| Continuous Operations Profit Margin | -277.5% | -1613.9% | -1574.2% | -9719.3% | -8539.4% | |
| Net Profit Margin | -277.5% | -1613.9% | -1574.2% | -9719.3% | -8539.4% | |
| Bottom Line Profit Margin | -277.5% | -1613.9% | -1574.2% | -9719.3% | -8539.4% | |
| Current Ratio | 11.972 | 10.658 | 0.954 | 2.191 | 2.480 | |
| Quick Ratio | 11.771 | 10.416 | 0.821 | 2.044 | 2.480 | |
| Solvency Ratio | -0.732 | -3.894 | -1.435 | -5.486 | -3.869 | |
| Cash Ratio | 3.135 | 2.785 | 0.595 | 1.790 | 2.259 | |
| Price To Earnings Ratio | -7.704 | -0.281 | -0.289 | -0.079 | -0.340 | |
| Price To Earnings Growth Ratio | 0.093 | -0.008 | 0.004 | -0.000 | -0.000 | |
| Forward Price To Earnings Growth Ratio | 0.093 | -0.008 | 0.004 | -0.000 | -0.000 | |
| Price To Earnings Diluted Ratio | -7.704 | -0.281 | -0.289 | -0.079 | -0.340 | |
| Price To Earnings Diluted Growth Ratio | 0.093 | -0.008 | 0.004 | -0.000 | -0.000 | |
| Price To Book Ratio | 1.220 | 0.227 | 0.116 | 0.091 | 0.045 | |
| Price To Sales Ratio | 21.375 | 4.534 | 4.556 | 7.636 | 29.029 | |
| Price To Free Cash Flow Ratio | -10.521 | -0.978 | -0.697 | -0.726 | -0.560 | |
| Price To Operating Cash Flow Ratio | -10.521 | -0.987 | -0.712 | -0.756 | -0.616 | |
| Debt To Assets Ratio | 0.034 | 0.023 | 0.019 | 0.017 | 0.011 | |
| Debt To Equity Ratio | 0.038 | 0.027 | 0.023 | 0.021 | 0.012 | |
| Debt To Capital Ratio | 0.037 | 0.026 | 0.023 | 0.020 | 0.012 | |
| Long Term Debt To Capital Ratio | 0.016 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.134 | 1.192 | 1.250 | 1.206 | 1.033 | |
| Working Capital Turnover Ratio | 0.182 | 0.342 | 1.216 | 0.364 | 0.044 | |
| Operating Cash Flow Ratio | -3.753 | -7.503 | -3.642 | -4.160 | -7.030 | |
| Operating Cash Flow Sales Ratio | -2.032 | -4.595 | -6.399 | -10.105 | -47.093 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.009 | 1.022 | 1.041 | 1.102 | |
| Debt Service Coverage Ratio | -21.511 | 0.000 | -40.264 | -40.900 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -25.523 | 0.000 | -40.232 | -42.093 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -3.051 | -8.470 | -7.059 | -5.846 | -6.224 | |
| Capital Expenditure Coverage Ratio | -328.941 | -110.821 | -46.233 | -24.555 | -9.841 | |
| Dividend Paid And Capex Coverage Ratio | -328.941 | -110.821 | -46.233 | -24.555 | -9.841 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -7.917 | -0.694 | -0.644 | -0.474 | -0.260 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | -42.5% | ▲19.6% | ▲177.8% |
| Ebit Margin | -363.2% | ▲248.5% | ▲2002.1% |
| Ebitda Margin | -256.9% | ▲228.9% | ▲1892.1% |
| Operating Profit Margin | -363.0% | ▲1380.1% | ▲4075.3% |
| Pretax Profit Margin | -363.2% | ▲1358.5% | ▲4068.5% |
| Continuous Operations Profit Margin | -277.5% | ▲1336.5% | ▲4067.4% |
| Net Profit Margin | -277.5% | ▲1336.5% | ▲4067.4% |
| Bottom Line Profit Margin | -277.5% | ▲1336.5% | ▲4067.4% |
| Current Ratio | 11.973 | ▲1.315 | ▲6.322 |
| Quick Ratio | 11.771 | ▲1.356 | ▲6.265 |
| Solvency Ratio | -0.732 | ▲3.162 | ▲2.351 |
| Cash Ratio | 3.135 | ▲0.349 | ▲1.022 |
| Price To Earnings Ratio | -7.704 | ▼-7.423 | ▼-5.965 |
| Price To Earnings Growth Ratio | 0.093 | ▲0.102 | ▲0.076 |
| Forward Price To Earnings Growth Ratio | 0.093 | ▲0.102 | ▲0.076 |
| Price To Earnings Diluted Ratio | -7.704 | ▼-7.423 | ▼-5.965 |
| Price To Earnings Diluted Growth Ratio | 0.093 | ▲0.102 | ▲0.076 |
| Price To Book Ratio | 1.220 | ▲0.993 | ▲0.880 |
| Price To Sales Ratio | 21.375 | ▲16.841 | ▲7.949 |
| Price To Free Cash Flow Ratio | -10.521 | ▼-9.543 | ▼-7.824 |
| Price To Operating Cash Flow Ratio | -10.521 | ▼-9.534 | ▼-7.802 |
| Debt To Assets Ratio | 0.034 | ▲0.011 | ▲0.013 |
| Debt To Equity Ratio | 0.038 | ▲0.011 | ▲0.014 |
| Debt To Capital Ratio | 0.037 | ▲0.010 | ▲0.013 |
| Long Term Debt To Capital Ratio | 0.017 | ▲0.017 | ▲0.013 |
| Financial Leverage Ratio | 1.133 | ▼-0.058 | ▼-0.029 |
| Working Capital Turnover Ratio | 0.182 | ▼-0.160 | ▼-0.247 |
| Operating Cash Flow Ratio | -3.753 | ▲3.750 | ▲1.464 |
| Operating Cash Flow Sales Ratio | -2.032 | ▲2.564 | ▲12.013 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | ▼-0.009 | ▼-0.035 |
| Debt Service Coverage Ratio | -21.512 | ▼-21.512 | ▼-0.976 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | -25.523 | ▼-25.523 | ▼-3.954 |
| Operating Cash Flow Coverage Ratio | -3.051 | ▲5.419 | ▲3.079 |
| Capital Expenditure Coverage Ratio | -328.941 | ▼-218.119 | ▼-224.863 |
| Dividend Paid And Capex Coverage Ratio | -328.941 | ▼-218.119 | ▼-224.863 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -7.917 | ▼-7.224 | ▼-5.920 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $3.15B | $569.4M | $424.2M | $424.2M | $424.2M | |
| Enterprise value | $2.99B | $423.3M | $411.3M | $278.6M | $313.6M | |
| EV / Sales | 20.34x | 3.37x | 4.42x | 5.01x | 21.46x | |
| EV / Op. cash flow | -10.01x | -0.73x | -0.69x | -0.50x | -0.46x | |
| EV / Free cash flow | -10.01x | -0.73x | -0.68x | -0.48x | -0.41x | |
| EV / EBITDA | -7.92x | -0.69x | -0.64x | -0.47x | -0.26x | |
| Net debt / EBITDA | 0.40x | 0.24x | 0.02x | 0.25x | 0.09x | |
| Current ratio | 11.97x | 10.66x | 0.95x | 2.19x | 2.48x | |
| Income quality | 0.73x | 0.28x | 0.41x | 0.10x | 0.55x | |
| Graham net-net | $16 | $10 | -$25 | -$22 | -$3 | |
| Tax burden | 76.4% | 93.7% | 97.2% | 99.2% | 98.6% | |
| Interest burden | 100.0% | 281.5% | 189.2% | 732.9% | 100.0% | |
| Working capital | $874.2M | $742.9M | -$7.5M | $160.7M | $144.8M | |
| Invested capital | $2.83B | $2.90B | $3.74B | $4.79B | $9.63B | |
| Return on assets | -14.0% | -67.9% | -32.2% | -96.4% | -12.8% | |
| Operating ROA | -18.1% | -58.1% | -29.8% | -71.0% | -24.2% | |
| Return on tangible assets | -38.1% | -209.7% | -149.4% | -461.8% | -267.6% | |
| Return on equity | -15.8% | -81.0% | -40.2% | -116.2% | -13.2% | |
| Return on invested capital | -14.3% | -70.3% | -33.4% | -98.5% | -12.9% | |
| Return on capital employed | -18.8% | -75.3% | -34.5% | -99.6% | -13.1% | |
| Earnings yield | -13.0% | -356.0% | -345.5% | -1272.8% | -294.2% | |
| Free cash flow yield | -9.5% | -102.3% | -143.5% | -137.7% | -178.7% | |
| Capex / Op. cash flow | -0.3% | -0.9% | -2.2% | -4.1% | -10.2% | |
| Capex / Depreciation | 0.6% | 3.3% | 8.1% | 14.8% | 119.6% | |
| Capex / Sales | 0.6% | 4.1% | 13.8% | 41.2% | 478.6% | |
| SG&A / Sales | 187.4% | 292.9% | 389.4% | 533.6% | 1601.8% | |
| R&D / Sales | 133.0% | 256.7% | 363.8% | 593.3% | 3149.5% | |
| Stock comp / Sales | 39.6% | 68.5% | 104.4% | 136.3% | 4666.8% | |
| Intangibles / Total assets | 63.3% | 67.6% | 78.5% | 79.1% | 95.2% | |
| Days sales outstanding | 45d | 72d | 88d | 122d | 172d | |
| Days payables outstanding | 4d | 9d | 38d | 37d | 56d | |
| Operating cycle | 73d | 105d | 130d | 164d | 172d | |
| Cash conversion cycle | 70d | 96d | 92d | 127d | 116d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+452.4%EV / Sales ▲+503.5%EV / EBITDA ▼-1041.1%EV / Op. cash flow ▼-9.280Earnings yield ▲+3.430
Profitability
Return on equity ▲+0.651Return on assets ▲+0.540Return on invested capital ▲+0.560Return on capital employed ▲+0.565Operating ROA ▲+0.400Income quality ▲+0.447Tax burden ▼-0.173
Efficiency
Days sales outstanding ▼-26.238Days payables outstanding ▼-5.058Operating cycle ▼-31.764Cash conversion cycle ▼-26.706Capex / Sales ▼-0.035R&D / Sales ▼-1.236
Balance-sheet strength
Current ratio ▲+1.315Net debt / EBITDA ▲+0.162Working capital ▲+131243000.000Invested capital ▼-66642000.000Intangibles / Total assets ▼-0.043
Change over 5 years
Valuation
Market cap ▲+641.6%EV / Sales ▼-5.2%EV / EBITDA ▼-2947.0%EV / Op. cash flow ▼-9.558Earnings yield ▲+2.812
Profitability
Return on equity ▼-0.026Return on assets ▼-0.012Return on invested capital ▼-0.014Return on capital employed ▼-0.057Operating ROA ▲+0.061Income quality ▲+0.181Tax burden ▼-0.222
Efficiency
Days sales outstanding ▼-126.535Days payables outstanding ▼-52.573Operating cycle ▼-98.663Cash conversion cycle ▼-46.089Capex / Sales ▼-4.779R&D / Sales ▼-30.165
Balance-sheet strength
Current ratio ▲+9.493Net debt / EBITDA ▲+0.310Working capital ▲+729333000.000Invested capital ▼-6804316000.000Intangibles / Total assets ▼-0.319
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-31 GRAIL to Present at Morgan Stanley''s 24th Annual Global Healthcare Conference MENLO PARK, Calif., Aug. 31, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Monday, Sep. 14 at 11:30 a.m.
- 2026-08-14 GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meeting GRAIL NASDAQ: GRAL Chief Financial Officer Aaron Freidin said the company''s Galleri multi-cancer early detection test recorded strong first-half growth as it expanded distribution through digital health platforms, employers and physician offices.
- 2026-08-13 Bank of America Corp DE Purchases 205,611 Shares of GRAIL, Inc. $GRAL Bank of America Corp DE raised its holdings in shares of GRAIL, Inc. (NASDAQ: GRAL) by 29.0% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 914,114 shares of the company''s stock after purchasing an additional 205,611 shares
- 2026-08-12 GRAIL: Looking Beyond The NHS-Galleri Headline GRAIL faces a binary FDA approval event for Galleri, with significant stock movement expected based on the outcome. Despite disappointing NHS-Galleri trial results, I believe the true value of the test would have been apparent with a longer monitoring period. While GRAL has a solid cash position, commercialization delays could see the company having to raise a large amount of capital on unfavorable terms.
- 2026-08-10 FDA Panel Schedules to Evaluate GRAIL Premarket Approval Application for Multi-Cancer Early Detection Test GRAIL Inc. (NASDAQ:GRAL) on Friday said it is preparing for a pivotal regulatory event as the U.S. Food and Drug Administration''s (FDA) Molecular and Clinical Genetics Panel gears up to evaluate the healthcare company''s flagship cancer diagnostic tool.
- 2026-08-07 GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri Multi-Cancer Early Detection Test
- 2026-08-07 US FDA to hold advisory meeting to review Grail''s multi-cancer test Grail said on Friday the U.S. FDA plans to hold a meeting of outside experts to review its multi-cancer screening test Galleri in September, sending its shares up 4% in morning trade.
- 2026-08-07 GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test MENLO PARK, Calif., Aug. 7, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the U.S. Food and Drug Administration''s (FDA) Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to meet on Sept.
- 2026-08-06 GRAIL, Inc. (GRAL) Q2 2026 Earnings Call Transcript GRAIL, Inc. (GRAL) Q2 2026 Earnings Call Transcript
- 2026-08-05 GRAIL Q2 Earnings Call Highlights GRAIL NASDAQ: GRAL reported second-quarter revenue growth driven by higher Galleri test volumes, while outlining continued efforts to secure FDA approval, expand its commercial organization and build international distribution partnerships.